Document:

Exclusive License Agreement

 EXHIBIT 10.9 
 Agreement No. 07-M0001 
 This draft is dated October 18,
2007, and is solely for purposes of negotiation. No contract shall exist until a final, written agreement is signed by MARSHFIELD CLINIC and an authorized representative of Licensee. This draft shall expire on November 10, 2007. 
 EXCLUSIVE LICENSE AGREEMENT 
 This Agreement is made effective the 15th day of October, 2007, by and between Marshfield Clinic (hereinafter called “MARSHFIELD CLINIC”), a nonstock,
nonprofit Wisconsin corporation, and Osmetech Molecular Diagnostics (hereinafter called “Licensee”), a corporation organized and existing under the laws of Delaware; 
 WHEREAS, MARSHFIELD CLINIC owns certain intellectual property rights to the inventions described in the “Licensed Patents” defined below, and MARSHFIELD CLINIC is
willing to grant a license to Licensee under any one or all of the Licensed Patents and Licensee desires a license under all of them; 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth below, the parties covenant and agree as follows: 
 Section 1: Definitions. 
 For the purpose of this Agreement, the Appendix A definitions shall apply. 
 Section 2: Grant. 
 A. License and Option.

 (i) MARSHFIELD CLINIC hereby grants to Licensee under the Licensed Patents an exclusive license to make, use
and sell Products in the Licensed Field and Licensed Territory. 
 (ii) MARSHFIELD CLINIC grants to Licensee an
exclusive option to license any warfarin molecular markers identified by inventors of MARSHFIELD CLINIC and solely owned by MARSHFIELD CLINIC that are identified before January 1, 2011. MARSHFIELD CLINIC also grants a non-exclusive option to
non-exclusively license warfarin molecular markers jointly owned by MARSHFIELD CLINIC, provided MARSHFIELD CLINIC is not restricted from doing so by agreement with joint owner. Such offer is conditional on Licensee’s satisfactory progress
towards market launch of Licensed Products, including receiving FDA approval (Appendix E), as determined by MARSHFIELD CLINIC. MARSHFIELD CLINIC shall notify Licensee in writing of any such markers in a timely manner, after such markers are
disclosed by the inventors to MARSHFIELD CLINIC. Upon receipt of notification, Licensee shall have thirty (30) days to provide written notice to MARSHFIELD CLINIC that Licensee desires to exercise such option. Upon MARSHFIELD CLINIC’S
receipt of such notice, MARSHFIELD CLINIC and Licensee shall enter into good faith negotiations regarding the terms of a license agreement and shall have ninety (90) days from the date of notice to negotiate such a license. If MARSHFIELD CLINIC
and Licensee fail to enter a license within such time period, the option granted shall terminate, unless extended by a written agreement signed by both parties, but only with respect to the specific warfarin molecular marker disclosed. 

(iii) In consideration of establishing a long-term collaboration, Licensee agrees to place an Osmetech eSensor XT-8
instrument at MARSHFIELD CLINIC and provide necessary training on or before March 31, 2008. The Licensee retains all rights to the equipment and may terminate the arrangement after a six (6) month advance notice. 
  

					
	 Osmetech Marshfield Exclusive License 07-M0001
	  	1 of 15	  	

 B. Sublicenses. 
 (i) Licensee may grant written, nonexclusive sublicenses to third parties. Any agreement granting a sublicense shall state
that the sublicense is subject to the termination of this Agreement. Licensee shall have the same responsibility for the activities of any sublicensee as if the activities were directly those of Licensee. Licensee shall provide MARSHFIELD CLINIC
with the name, contact information and address of each sublicensee, as well as information regarding the number of full-time employees of any such sublicensee to allow MARSHFIELD CLINIC to determine whether it can maintain its small entity filing
status for patent prosecution and maintenance purposes. 
 (ii) With respect to sublicenses granted by Licensee
under this Section 2B, Licensee shall pay to MARSHFIELD CLINIC an amount equal to what Licensee would have been required to pay to MARSHFIELD CLINIC had Licensee sold the amount of Products sold by such sublicensee. In addition, Licensee shall
pay to MARSHFIELD CLINIC    ***    of all upfronts, milestone payments, penalties, or other payments in consideration of the sublicense, exclusive of royalties owed. Licensee shall not receive from its
sublicensees anything of value in lieu of cash payments in consideration for any sublicense granted under this Agreement without the express prior written consent of MARSHFIELD CLINIC. 
 C. Reservation of Rights. 
 MARSHFIELD CLINIC hereby reserves the right to grant non-profit research institutions and governmental agencies non-exclusive licenses to practice and use the inventions of the
Licensed Patents for Non-Commercial Research Purposes. Marshfield Clinic and the inventors of the Licensed Patents shall have the right to publish any information included in the Licensed Patents. 
 D. License to MARSHFIELD CLINIC. 
 (i) Licensee hereby grants, and shall require its sublicensee(s) to grant, to MARSHFIELD CLINIC a nonexclusive, royalty-free, irrevocable, paid-up license, with the right to grant
sublicenses to non-profit research institutions and governmental agencies, to practice and use of the Licensed Patents and “Improvements” for Non-Commercial Research Purposes. “Improvements” shall mean any patented modification
of an invention described in the Licensed Patents that (1) would be infringed by the practice of an invention claimed in the Licensed Patents; or (2) if not for the license granted under this Agreement, would infringe one or more claims of
the Licensed Patents. Licensee shall provide MARSHFIELD CLINIC with a written, enabling disclosure of each such invention, unambiguously identifying it as an invention governed by this paragraph, within six (6) months of the issuance of a
patent thereon. 
 (ii) In the event that Licensee and its sublicensee(s) discontinue the use or
commercialization of the Licensed Patents or any Improvements provided for under this Agreement, Licensee shall grant, and shall require its sublicensee(s) to grant, to MARSHFIELD CLINIC an option to obtain a nonexclusive, royalty-bearing license,
with the right to grant sublicenses, to practice and use said Improvements for commercial purposes. Licensee shall provide to MARSHFIELD CLINIC written notice that Licensee and its sublicensee(s) intend to discontinue such use or commercialization
immediately upon making such a decision. Marshfield Clinic’s option with respect to each Improvement shall expire sixty (60) days after Marshfield Clinic’s receipt of said written notice from Licensee. The failure of MARSHFIELD CLINIC
to timely exercise its option under this paragraph shall be deemed a waiver of Marshfield Clinic’s option, but only with respect to the Improvement so disclosed. 
  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

  

					
	 Osmetech Marshfield Exclusive License 07-M0001
	  	2 of 15	  	

 Section 3: Development. 
 A. Licensee shall diligently develop, manufacture, market and sell Products in each Licensed Field and Licensed Territory
throughout the term of this Agreement. Such activities shall include, without limitation, those activities listed in the Development Plan attached hereto as Appendix E. Licensee agrees that said Development Plan is reasonable and that it shall
take all reasonable steps to meet the development program as set forth therein. 
 B. Beginning in calendar
year 2008 and until the Date of First Commercial Sale, Licensee shall provide MARSHFIELD CLINIC with a written Development Report summarizing Licensee’s development activities since the last Development Report and any necessary adjustments to
the Development Plan. Licensee agrees to provide each Development Report to MARSHFIELD CLINIC on or before thirty (30) days from the end of each semi-annual period ending June 30 and December 31 for which a report is due, and shall
set forth in each Development Report sufficient detail to enable MARSHFIELD CLINIC to ascertain Licensee’s progress toward the requirements of the Development Plan. MARSHFIELD CLINIC reserves the right to audit Licensee’s records relating
to the development activities required hereunder. Such record keeping and audit procedures shall be subject to the procedures and restrictions set forth in Section 6 for auditing the financial records of Licensee. 
 C. Licensee agrees to and warrants that it has, or will obtain, the expertise necessary to independently evaluate the
inventions of the Licensed Patents and to develop Products for sale in the commercial market and that it so intends to develop Products for the commercial market. Licensee acknowledges that any failure by Licensee to reasonably implement the
Development Plan, or to make timely submission to MARSHFIELD CLINIC of any Development Report, or the providing of any false information to MARSHFIELD CLINIC regarding Licensee’s development activities hereunder, shall be a material breach of
this Agreement. 
 Section 4: Consideration. 
  

	 	A.	 License Fee. 

     ***     
  

	 	B.	 Royalty. 

 In addition to the Section 4A license fee, Licensee agrees to pay to MARSHFIELD CLINIC as “earned royalties” a royalty calculated as a percentage of the Selling Price of Products in
accordance with the terms and conditions of this Agreement. The royalty is deemed earned as of the earlier of the date the Product is actually sold, leased or otherwise transferred for consideration, the date an invoice is sent by Licensee, or the
date a Product is transferred to a third party for any promotional reasons. The royalty shall remain fixed while this Agreement is in effect at a rate of     ***     of the Selling Price of Products.

  

	 	C.	 Minimum Royalty. 

 Licensee further agrees to pay to MARSHFIELD CLINIC a minimum royalty of    ***    per calendar year or part thereof during which this Agreement is in effect
starting in calendar year 2009, against which any earned royalty paid for the same calendar year will be credited provided that MARSHFIELD CLINIC proves clinical utility for its SNP rs2108622 in the gene CYP4F2 through

  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

  

					
	 Osmetech Marshfield Exclusive License 07-M0001
	  	3 of 15	  	

 
clinical validation studies. Such validation studies are being conducted at MARSHFIELD CLINIC now in partnership with external collaborators. Positive results of such studies will be considered
as proof of clinical validation. Unless and until Marshfield Clinic secures such validation, no obligation will exist for Licensee to pay such minimum royalty. The minimum royalty for a given year shall be due at the time payments are due for the
calendar quarter ending on December 31. It is understood that the minimum royalties will apply on a calendar year basis, and that sales of Products requiring the payment of earned royalties made during a prior or subsequent calendar year shall
have no effect on the annual minimum royalty due MARSHFIELD CLINIC for any other given calendar year. 
 D.
Patent Fees and Costs. 
 MARSHFIELD CLINIC has
authorized    ***    to file, prosecute and maintain patent coverage of the Licensed Patent or patent application on its behalf. Therefore,    ***    shall be the
contact agency for Licensee regarding all matters described in this Section 4D. 
 (i) Licensee also
agrees to reimburse MARSHFIELD CLINIC for    ***    of all reasonable costs incurred by MARSHFIELD CLINIC in filing, prosecuting and maintaining the Licensed Patents in US, EU and Japan. All such costs for
each Licensed Patent shall come due only after the applicable patent office has issued a notification of allowance (or its equivalent), and shall be paid by Licensee within thirty (30) days of receipt of an invoice from MARSHFIELD CLINIC,
or    ***    , acting on behalf of MARSHFIELD CLINIC. 
 (ii)
MARSHFIELD CLINIC is not obligated to make or maintain any foreign filing of the Licensed Patents other than agreeing that it shall make and maintain US, EU (7 selected countries in Europe) and Japan filings of the Licensed Patents. If Licensee
desires MARSHFIELD CLINIC to make or maintain other foreign filings, Licensee must notify MARSHFIELD CLINIC in writing three (3) months prior to the expiration of the deadline for making such foreign filings, indicating those countries in which
Licensee desires MARSHFIELD CLINIC to pursue foreign patent protection. Licensee agrees to pay all reasonable patenting costs for additional countries within thirty (30) days of receiving an invoice from MARSHFIELD CLINIC. Any country for which
MARSHFIELD CLINIC files for such patent protection at Licensee’s request shall be included in the Licensed Territory under this Agreement. MARSHFIELD CLINIC reserves the right to file a patent application, at its own expense, in any countries
not requested by Licensee pursuant to this Section 4D. Licensee acknowledges that if the United States Government (through any of its agencies or otherwise) has funded research, during the course of or under which any of the inventions of the
Licensed Patents were conceived or made, the United States Government is entitled, as a right, under the provisions of 35 U.S.C. § 200-212 and applicable regulations of Chapter 37 of the Code of Federal Regulations, to make and
maintain foreign filings in those countries not selected by Licensee and/or MARSHFIELD CLINIC. 
  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

  

					
	 Osmetech Marshfield Exclusive License 07-M0001
	  	4 of 15	  	

 (iii) MARSHFIELD CLINIC will prosecute all national applications it files
at Licensee’s request pursuant to this Section 4D until MARSHFIELD CLINIC determines that continued prosecution is unlikely to result in the issuance of a patent in that country. If MARSHFIELD CLINIC decides to abandon prosecution or
maintenance of any patent or patent application under the Licensed Patents in a country in which Licensee has requested MARSHFIELD CLINIC to make and maintain such filing, MARSHFIELD CLINIC shall provide Licensee notice of Marshfield Clinic’s
intent to abandon such application. In such event, Licensee shall have the right to continue prosecution of said application, at its own expense, on behalf of MARSHFIELD CLINIC and Licensee, to the extent allowed under applicable law. 
 E. Accounting; Payments. 
 (i) Amounts owing to MARSHFIELD CLINIC under Sections 2B and 4B shall be paid on a quarterly basis, with such amounts due and received by MARSHFIELD CLINIC on or before the
thirtieth (30th) day following the end of the
calendar quarter ending on March 31, June 30, September 30 or December 31 in which such amounts were earned. The balance of any amounts which remain unpaid more than thirty (30) days after they are due to MARSHFIELD CLINIC
shall accrue interest until paid at the rate of the lesser of    ***    per month or the maximum amount allowed under applicable law. However, in no event shall this interest provision be construed as a grant
of permission for any payment delays. 
 (ii) Except as otherwise directed, all amounts owing to MARSHFIELD
CLINIC under this Agreement shall be paid in U.S. dollars to MARSHFIELD CLINIC at the address provided in Section 16(a). All royalties owing with respect to Selling Prices stated in currencies other than U.S. dollars shall be converted at the
rate shown in the Federal Reserve Noon Valuation - Value of Foreign Currencies on the day preceding the payment. MARSHFIELD CLINIC is exempt from paying income taxes under U.S. law. Therefore, all payments due under this Agreement shall be made
without deduction for taxes, assessments, or other charges of any kind which may be imposed on MARSHFIELD CLINIC by any government outside of the United States or any political subdivision of such government with respect to any amounts payable to
MARSHFIELD CLINIC pursuant to this Agreement. All such taxes, assessments, or other charges shall be assumed by Licensee. 
 (iii) A full accounting showing how any amounts owing to MARSHFIELD CLINIC under Sections 2B and 4B have been calculated shall be submitted to MARSHFIELD CLINIC on the date of each such payment. Such
accounting shall be on a per-country and product line, model or trade name basis and shall be summarized on the form shown in Appendix C of this Agreement. In the event no payment is owed to MARSHFIELD CLINIC, a statement setting forth that
fact shall be supplied to MARSHFIELD CLINIC. 
 Section 5: Certain Warranties. 
 A. MARSHFIELD CLINIC warrants that except as otherwise provided under Section 14 of this Agreement with respect to U.S.
Government interests, it is the owner of the Licensed Patents or otherwise has the right to grant the licenses granted to Licensee in this Agreement. However, nothing in this Agreement shall be construed as: 
 (i) a warranty or representation by MARSHFIELD CLINIC as to the validity or scope of any of the Licensed Patents;

  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

  

					
	 Osmetech Marshfield Exclusive License 07-M0001
	  	5 of 15	  	

 (ii) a warranty or representation that anything made, used, sold or
otherwise disposed of under the license granted in this Agreement will or will not infringe patents of third parties; or 
 (iii) an obligation to furnish any know-how not provided in the Licensed Patents or any services other than those specified in this Agreement. 
 B. MARSHFIELD CLINIC MAKES NO REPRESENTATIONS, EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND ASSUMES NO
RESPONSIBILITIES WHATSOEVER WITH RESPECT TO THE USE, SALE, OR OTHER DISPOSITION BY LICENSEE, ITS SUBLICENSEE(S), OR THEIR VENDEES OR OTHER TRANSFEREES, OF PRODUCTS INCORPORATING OR MADE BY USE OF INVENTIONS LICENSED UNDER THIS AGREEMENT. 

C. Licensee represents and warrants that Products produced under the license granted herein shall be manufactured
substantially in the United States as required by 35 U.S.C. § 204 and applicable regulations of Chapter 37 of the Code of Federal Regulations. 
 Section 6: Recordkeeping. 
 A.
Licensee and its sublicensee(s) shall keep books and records sufficient to verify the accuracy and completeness of Licensee’s and its sublicensee(s)’s accounting referred to above, including, without limitation, inventory, purchase and
invoice records relating to the Products or their manufacture. In addition, Licensee shall maintain documentation evidencing that Licensee is in fact pursuing the development of Products as required herein. Such documentation may include, but is not
limited to, invoices for studies advancing the development of Products, laboratory notebooks, internal job cost records, and filings made to the Internal Revenue Department to obtain tax credit, if available, for research and development of
Products. Such books and records shall be preserved for a period not less than six (6) years after they are created during and after the term of this Agreement. 
 B. Licensee and its sublicensee(s) shall take all steps necessary so that MARSHFIELD CLINIC may within thirty (30) days of its request review and copy all the books and records
at a single U.S. location to allow MARSHFIELD CLINIC to verify the accuracy of Licensee’s royalty reports and Development Reports and the royalty reports of its sublicensee(s). Such review may be performed by any employee of MARSHFIELD CLINIC
as well as by any attorney or registered CPA designated by MARSHFIELD CLINIC, upon reasonable notice and during regular business hours. 
 C. If a royalty payment deficiency is determined, Licensee and its sublicensee(s), as applicable, shall pay the royalty deficiency outstanding within thirty (30) days of receiving written notice
thereof, plus interest on outstanding amounts as described in Section 4E(i). 
 D. If a royalty payment
deficiency for a calendar year exceeds the lesser of    ***    of the royalties paid for that year or    ***    then Licensee or its sublicensee(s) shall be responsible
for paying Marshfield Clinic’s out-of-pocket expenses incurred with respect to such review. 
 Section 7:
Term and Termination. 
 A. The term of this license shall begin on the effective date of this Agreement
and continue until this Agreement is terminated as provided herein or until the earlier of the date that no

  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

  

					
	 Osmetech Marshfield Exclusive License 07-M0001
	  	6 of 15	  	

 
Licensed Patent remains an enforceable patent or the payment of earned royalties under Sections 2B and 4B, once begun, ceases for more than eight (8) calendar quarters. 
 B. Licensee may terminate this Agreement at any time by giving at least ninety (90) days written and unambiguous notice
of such termination to MARSHFIELD CLINIC. Such a notice shall be accompanied by a statement of the reasons for termination. 
 C. MARSHFIELD CLINIC shall have the right to terminate this Agreement if Licensee fails to offer for sale to the retail market a diagnostic Product (APPENDIX A) by January 1, 2011 by giving
Licensee at least ninety (90) days written notice. 
 D. If Licensee at any time defaults in the timely
payment of any monies due to MARSHFIELD CLINIC or the timely submission to MARSHFIELD CLINIC of any Development Report, fails to actively pursue the development plan, or commits any breach of any other covenant herein contained, and Licensee fails
to remedy any such breach or default within ninety (90) days after written notice thereof by MARSHFIELD CLINIC, or if Licensee commits any act of bankruptcy, becomes insolvent, is unable to pay its debts as they become due, files a petition
under any bankruptcy or insolvency act, or has any such petition filed against it which is not dismissed within sixty (60) days, or if Licensee or its sublicensee(s) offer any component of the Licensed Patents to their creditors, MARSHFIELD
CLINIC may, at its option, terminate this Agreement by giving notice of termination to Licensee. 
 E. Upon the
termination of this Agreement, Licensee and its sublicensee(s) shall remain obligated to provide an accounting for and to pay royalties earned up to the date of the termination, and any minimum royalties shall be prorated as of the date of
termination by the number of days elapsed in the applicable calendar year. 
 F. Waiver by either party of a
single breach or default, or a succession of breaches or defaults, shall not deprive such party of any right to terminate this Agreement in the event of any subsequent breach or default. 
 Section 8: Assignability. 
 This Agreement may not be transferred or assigned by Licensee without the prior written consent of MARSHFIELD CLINIC, except upon the sale of substantially all of the Licensee’s
assets, in which case no consent for such assignment is required. 
 Section 9: Contest of Validity.

 In the event Licensee or its sublicensee(s) contest the validity or enforceability of any Licensed Patent,
Licensee and its sublicensee(s) shall continue to pay royalties with respect to that patent as if such contest were not underway until the patent is adjudicated invalid or unenforceable by a court of last resort. 
 Section 10: Enforcement. 
 MARSHFIELD CLINIC intends to protect the Licensed Patents against infringers or otherwise act to eliminate infringement when, in Marshfield Clinic’s sole judgment, such action
may be necessary, proper, justified and makes reasonable business sense considering all factors. In the event that Licensee or its sublicensee(s) believe there is infringement of any Licensed Patent under this Agreement which is to its substantial
detriment, Licensee shall provide MARSHFIELD CLINIC with notification and reasonable evidence of such infringement. 
  

					
	 Osmetech Marshfield Exclusive License 07-M0001
	  	7 of 15	  	

 Section 11: Patent Marking. 
 Licensee and its sublicensee(s) shall mark all Products or Product packaging with the appropriate patent number reference in
compliance with the requirements of U.S. law, 35 U.S.C. § 287. 
 Section 12: Product Liability;
Conduct of Business. 
 A. Licensee shall, at all times during the term of this Agreement and thereafter,
indemnify, defend and hold MARSHFIELD CLINIC and the inventors of the Licensed Patents harmless against all claims and expenses, including legal expenses and reasonable attorneys fees, arising out of the death of or injury to any person or persons
or out of any damage to property and against any other claim, proceeding, demand, expense and liability of any kind whatsoever resulting from the production, manufacture, sale, use, lease, consumption or advertisement of Products arising from any
right or obligation of Licensee or its sublicensee(s) hereunder. MARSHFIELD CLINIC at all times reserves the right to select and retain counsel of its own to defend Marshfield Clinic’s interests. 
 B. Licensee warrants that it now maintains and will continue to maintain liability insurance coverage appropriate to the
risk involved in marketing the products subject to this Agreement and that such insurance coverage lists MARSHFIELD CLINIC and the inventors of the Licensed Patents as additional insureds. Within ninety (90) days after the execution of this
Agreement and thereafter annually between January 1 and January 31 of each year, Licensee will present evidence to MARSHFIELD CLINIC that the coverage is being maintained with MARSHFIELD CLINIC and its inventors listed as additional
insureds. In addition, Licensee shall provide MARSHFIELD CLINIC with at least thirty (30) days prior written notice of any change in or cancellation of the insurance coverage. 
 Section 13: Use of Names. 
 Neither Licensee nor its sublicensee(s) shall use Marshfield Clinic’s name, the name of any inventor of inventions governed by this Agreement, in sales promotion, advertising,
or any other form of publicity without the prior written approval of the entity or person whose name is being used; except that one or more press releases evidencing the existence of this Agreement may be undertaken by the parties, said releases to
be jointly-approved between them prior to release. 
 Section 14: United States Government Interests.

 It is understood that if the United States Government (through any of its agencies or otherwise) has funded
research, during the course of or under which any of the inventions of the Licensed Patents were conceived or made, the United States Government is entitled, as a right, under the provisions of 35 U.S.C. §§ 200-212 and applicable
regulations of Chapter 37 of the Code of Federal Regulations, to a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced the invention of such Licensed Patents for governmental purposes. Any license granted
under this Agreement to Licensee or any of its sublicensee shall be subject to such right. 
 Section 15:
Miscellaneous. 
 This Agreement shall be governed by and construed in all respects in accordance with the
laws of the State of Wisconsin. If any provisions of this Agreement are or shall come into conflict with the laws or regulations of any jurisdiction or any governmental entity having jurisdiction over the parties or this Agreement, those provisions
shall be deemed automatically deleted, if such deletion is allowed by relevant law, and the remaining terms and conditions of this Agreement shall remain in full force and effect. If such a deletion is not so allowed or if such a deletion leaves
terms thereby made clearly illogical

  

					
	 Osmetech Marshfield Exclusive License 07-M0001
	  	8 of 15	  	

 
or inappropriate in effect, the parties agree to substitute new terms as similar in effect to the present terms of this Agreement as may be allowed under the applicable laws and regulations. The
parties hereto are independent contractors and not joint venturers or partners. 
 Section 16: Notices.

 Any notice required to be given pursuant to the provisions of this Agreement shall be in writing and shall be
deemed to have been given at the earlier of the time when actually received as a consequence of any effective method of delivery, including but not limited to hand delivery, transmission by telecopier, or delivery by a professional courier service
or the time when sent by certified or registered mail addressed to the party for whom intended at the address below or at such changed address as the party shall have specified by written notice, provided that any notice of change of address shall
be effective only upon actual receipt. 
  

			
	 (a)
	  	 ***

		  	 ***

		  	 ***

		  	 ***

		
	(b)	  	Licensee Osmetech Molecular Diagnostics Inc.
		  	Attn: Legal Department
		  	757 S. Raymond Ave
		  	Pasadena, CA 91105

 Section
17: Integration. 
 This Agreement constitutes the full understanding between the parties with reference
to the subject matter hereof, and no statements or agreements by or between the parties, whether orally or in writing, except as provided for elsewhere in this Section 17, made prior to or at the signing hereof, shall vary or modify the written
terms of this Agreement. Neither party shall claim any amendment, modification, or release from any provisions of this Agreement by mutual agreement, acknowledgment, or otherwise, unless such mutual agreement is in writing, signed by the other
party, and specifically states that it is an amendment to this Agreement. 
 Section 18: Confidentiality.

 The parties hereto agree to keep any information identified as confidential by the disclosing party
confidential using methods at least as stringent as each party uses to protect its own confidential information. “Confidential Information” shall include Licensee’s development plan and development reports, the Licensed Patents and
all information concerning them and any other information marked confidential or accompanied by correspondence indicating such information is exchanged in confidence between the parties. Except as may be authorized in advance in writing by
MARSHFIELD CLINIC, Licensee shall only grant access to Marshfield Clinic’s Confidential Information to its sublicensee(s) and those employees of Licensee and its sublicensee(s) involved in research relating to the Licensed Patents. Licensee
shall require its sublicensee(s) and all such employees to be bound by terms of confidentiality no less restrictive than those set forth in this Section 18. Licensee and its sublicensee(s) shall not use any Confidential Information to
Marshfield Clinic’s detriment, including, but not limited to, claiming priority to the Licensed Patents in any patent prosecution. The confidentiality and use obligations set forth above apply to all or any part of the Confidential Information
disclosed hereunder except to the extent that: 
  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

  

					
	 Osmetech Marshfield Exclusive License 07-M0001
	  	9 of 15	  	

 (i) MARSHFIELD CLINIC, Licensee or its sublicensee(s) can show by written
record that it possessed the information prior to its receipt from the other party; 
 (ii) the information was
already available to the public or became so through no fault of MARSHFIELD CLINIC, Licensee or its sublicensee(s); 
 (iii) the information is subsequently disclosed to MARSHFIELD CLINIC, Licensee or its sublicensee(s) by a third party that has the right to disclose it free of any obligations of confidentiality; or 
 (iv) five (5) years have elapsed from the expiration of this Agreement. 
 Section 19: Authority. 
 The persons signing on behalf of MARSHFIELD CLINIC and Licensee hereby warrant and represent that they have authority to execute this Agreement on behalf of the party for whom they have signed.

 IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement on the dates indicated below.

  

					
	 MARSHFIELD CLINIC

			
	 By:
	 	 /s/ Robert A. Carlson
	 	 Date: Oct 20, 2007

  

							
	Name and Office:	 	 /s/ Robert A. Carlson, MD – Director
 Applied Sciences
	 	

  

					
	 OSMETECH MOLECULAR DIAGNOSTICS

			
	 By:
	 	 /s/ James White
	 	 Date: 23rd October, 2007

  

							
	Name and Office:	 	 James White C.E.O.
	 	

					
	  
	 	

  

					
	 Reviewed by Marshfield Clinic’s Attorney:

		
	 /s/ illegible
	 	 Oct. 22, 2007

 (Marshfield Clinic’s attorney shall not be deemed a signatory to this Agreement.) 
 Marshfield Clinic Ref:
Caldwell - M07015US 
  

					
	 Osmetech Marshfield Exclusive License 07-M0001
	  	10 of 15	  	

 APPENDIX A 
 A. “Licensed Patents” shall refer to and mean those patents and patent applications listed on Appendix B attached
hereto in countries in the Licensed Territory and any subsequent patent application owned by MARSHFIELD CLINIC in a country in the Licensed Territory but only to the extent it claims priority to an invention claimed in a patent application listed on
Appendix B. This includes but is not limited to continuation applications, continuation-in-part applications to the extent they relate back to a parent Licensed Patent, divisional applications, reissue applications, utility model applications or
registrations, 
 B. “Products” shall refer to and mean any and all products that employ or are in any
way produced by the practice of an invention claimed in the Licensed Patents or that would otherwise constitute infringement of any claims of the Licensed Patents. 
 C. “Selling Price” shall mean, in the case of Products that are sold or leased, the invoice price to the end user of Products (regardless of uncollectible accounts) less
any shipping costs, allowances because of returned Products, or sales taxes. The “Selling Price” for a Product that is transferred to a third party for promotional purposes without charge or at a discount shall be the average invoice price
to the end user of that type of Product during the applicable calendar quarter. 
 D. “Development
Report” shall mean a written account of Licensee’s progress under the development plan having at least the information specified on Appendix D to this Agreement, and shall be sent to the address specified on Appendix D. 
 E. “Licensed Field” shall be limited to the field of human diagnostic and research applications, expressly
excluding any pharmaceutical drug development and therapeutic uses. 
 F. “Licensed Territory”
shall be Worldwide 
 G. “Non-Commercial Research Purposes” shall mean the use of the inventions of
the Licensed Patents and/or Improvements for academic research purposes or other not-for-profit or scholarly purposes not involving the use of the inventions of the Licensed Patents or Improvements to perform services for a fee or for the production
or manufacture of products for sale to third parties. 
  

					
	 Osmetech Marshfield Exclusive License 07-M0001
	  	11 of 15	  	

 APPENDIX B 
 LICENSED PATENTS 
  

									
	 REFERENCE NUMBER
	  	COUNTRY	  	PATENT
NUMBER	  	ISSUE
DATE	  	APPLICATION
SERIAL NUMBER
					
	Technology Title (Inventors...)	  		  		  		  	
	
	 *** “Test of rs2108622 in the gene CYP4F2 for predicting a patient’s starting dose of warfarin and subsequent dose adjustments”

	
	 This invention provides a method for improving warfarin dosing and dose adjustment models by adding data from a genetic test about single nucleotide
polymorphism rs2108622 in the gene CYP4F2 (Cytochrome P450 4F2.

					
	 ***
	  	 UNITED STATES
	  		  		  	

 A provisional US application will be filed by October 22, 2007. Licensee has
instructed    ***    to file in US, Europe and Japan. US, Europe and Japan applications are included in the “Licensed Patents” 
  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

  

					
	 Osmetech Marshfield Exclusive License 07-M0001
	  	12 of 15	  	

 APPENDIX C 
 MARSHFIELD CLINIC ROYALTY REPORT 
  

																	
	Licensee:	 	 	 	 	  	        Agreement No:	  	 	  	 
	Inventor:	 	 	 	 	  	        P#:	  		  	
	Period Covered:From:	 	            /            /            	  	         Through
	  	            /            /            
	Prepared By:	 	 	 	 	  	        Date:	  	 	  	 	  	 	  	 	  	 
	Approved By:	 	 	 	 	  	        Date:	  	 	  	 	  	 	  	 	  	 

 If license covers several major
product lines, please prepare a separate report for each line. Then combine all product lines into a summary report. 
  

																					
	Report Type:	  	  ̈
	 	 Single Product Line Report:
	  	 
						
		  	  ̈
	 	 Multiproduct Summary Report.     Page 1 of
	 	 	  	 Pages
	  	
								
		  	  ̈
	 	 Product Line Detail. Line:
	  	 	 	 Tradename:
	 	 	 	     Page:
	 	 
					
	Report Currency:	  	  ̈
	 	 U.S. Dollars
	  	  ̈Other
	 	 

  

													
	 	  	 	  	 	  	 	  	 	  	Period Royalty
Amount
	 Country
	  	Gross
Sales	  	* Less:
Allowances	  	Net
Sales	  	Royalty
Rate	  	This Year	  	Last Year
	 U.S.A.
	  		  		  		  		  		  	
	 Canada
	  		  		  		  		  		  	
	 Europe:
	  		  		  		  		  		  	
							
	 Japan
	  		  		  		  		  		  	
	 Other:
	  		  		  		  		  		  	
							
	 TOTAL:
	  		  		  		  		  		  	

  

											
	 Total Royalty:
	 	  
	 	 Conversion Rate:
	 	  
	  	 Royalty in U.S. Dollars:
	  	 $

 The following royalty forecast is non-binding and for Marshfield Clinic’s internal planning purposes only: 
  

													
	 Royalty Forecast Under This Agreement:
	  	 Next Quarter:
	  	 	  	 Q2:
	  	 	  	 Q3:
	  	 

													
	 Q4:
	  	 	  		  		  		  		  	

  

	*	 On a separate page, please indicate the reasons for returns or other adjustments if significant. 

 Also note any unusual occurrences that affected royalty amounts during this period. 
 To assist Marshfield Clinic’s forecasting, please comment on any significant expected trends in sales volume. 
  

					
	 Osmetech Marshfield Exclusive License 07-M0001
	  	13 of 15	  	

 APPENDIX D 
 DEVELOPMENT REPORT 
  

	A.	 Date development plan initiated and time period covered by this report. 

  

	B.	 Development Report (4-8 paragraphs). 

  

	 	1.	 Activities completed since last report including the object and parameters of the development, when initiated, when completed and the results.

  

	 	2.	 Activities currently under investigation, i.e., ongoing activities including object and parameters of such activities, when initiated, and projected
date of completion. 

  

	C.	 Future Development Activities (4-8 paragraphs). 

  

	 	1.	 Activities to be undertaken before next report including, but not limited to, the type and object of any studies conducted and their projected
starting and completion dates. 

  

	 	2.	 Estimated total development time remaining before a product will be commercialized. 

  

	D.	 Changes to initial development plan (2-4 paragraphs). 

  

	 	1.	 Reasons for change. 

  

	 	2.	 Variables that may cause additional changes. 

  

	E.	 Items to be provided if applicable: 

  

	 	1.	 Information relating to Product that has become publicly available, e.g., published articles, competing products, patents, etc.

  

	 	2.	 Development work being performed by third parties other than Licensee to include name of third party, reasons for use of third party, planned future
uses of third parties including reasons why and type of work. 

  

	 	3.	 Update of competitive information trends in industry, government compliance (if applicable) and market plan. 

 PLEASE SEND DEVELOPMENT REPORTS TO: 
 *** 
 *** 
 *** 
  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

  

					
	 Osmetech Marshfield Exclusive License 07-M0001
	  	14 of 15	  	

 APPENDIX E 
 DEVELOPMENT PLAN 
  

					
	 4F2 Development Plan Activities
	  	Timing	  	Status
		  		  	

 *** 
 *** 
 *** 
  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

  

					
	 Osmetech Marshfield Exclusive License 07-M0001
	  	15 of 15Non-Exclusive Patent License Agreement

 EXHIBIT 10.10 
 NON-EXCLUSIVE PATENT LICENSE AGREEMENT 
 BETWEEN 
 OSMETECH 
 AND 
 THE UNIVERSITY OF WASHINGTON 
 UW REFERENCE:
7063-18921A 
 UW TECHTRANSFER, INVENTION LICENSING 
 NEGOTIATED BY CHRISTINE HAN, PH.D., M.P.H. 
  

 UW/Osmetech Non-Exclusive Patent License Agreement 
 UW Reference 7063-18921A 
 Original Two of Two 
 Page 1 of 18 

 TABLE OF CONTENTS 
  

					
	 	  	 	  	Page
	1.0	  	 Definitions
	  	1
			
	2.0	  	 Term
	  	2
			
	3.0	  	 Grant of License
	  	2
			
	4.0	  	 Applications and Patents
	  	3
			
	5.0	  	 Commercialization
	  	4
			
	6.0	  	 Payments, Reimbursements, Reports, and Records
	  	5
			
	7.0	  	 Third Party Infringement of Licensed Patent
	  	6
			
	8.0	  	 Termination
	  	7
			
	9.0	  	 Release, Indemnification, and Insurance
	  	7
			
	10.0	  	 Warranties
	  	8
			
	11.0	  	 Damages
	  	9
			
	12.0	  	 Amendment and Waiver
	  	9
			
	13.0	  	 Assignment
	  	9
			
	14.0	  	 Applicable Law
	  	10
			
	15.0	  	 Confidentiality
	  	10
			
	16.0	  	 Consent and Approvals
	  	11
			
	17.0	  	 Construction
	  	11
			
	18.0	  	 Enforceability
	  	11
			
	19.0	  	 Entire Agreement; No Third-Party Beneficiaries
	  	11
			
	20.0	  	 Language and Currency
	  	11
			
	21.0	  	 Notices
	  	11
			
	22.0	  	 Publicity
	  	12
			
	23.0	  	 Relationship of Parties
	  	12
			
	24.0	  	 Security Interest
	  	12
			
	25.0	  	 Survival
	  	13
			
	26.0	  	 Collection Costs and Attorneys’ Fees
	  	13
			
	27.0	  	 Forum Selection
	  	13
			
	28.0	  	 Patent Marking
	  	13
			
		  	 Signatures
	  	13
			
		  	 Exhibit A
	  	14
			
		  	 Exhibit B
	  	16

 UW/Osmetech
Non-Exclusive Patent License Agreement 
 UW Reference 7063-18921A 
 Original Two of Two 

 NON-EXCLUSIVE PATENT LICENSE AGREEMENT 
 This Agreement (“Agreement”) is dated and effective as of the date of last signature (the “Effective
Date”), and is made by and between the University of Washington, a public institution of higher education and an agency of the state of Washington (the “University”), and Osmetech Molecular Diagnostics, an entity consisting solely of
Clinical Micro Sensors, Inc. and Osmetech, Inc., both Delaware Corporations (the “Company”), (individually a “Party” or collectively the “Parties”). 
 Purpose 
 The University owns the
right to license to others certain rights to the Licensed Patents, as that term is defined and used in this Agreement. The Company desires that the University grant it a license to use, develop, and commercialize the inventions claimed in the
Licensed Patents. The University is willing to grant such a license on the terms set forth below. 
 NOW, THEREFORE, the
Parties agree that: 
 1. Definitions. For purposes of interpreting this Agreement, the following terms shall have
the meanings ascribed to them below in this Article 1: 
  

	1.1	 “Affiliate” means (i) a Third Party that owns fifty percent (50%) or more of the voting capital stock, or like equity security,
of the Company, or (ii) a Third Party in which the Company owns fifty percent (50%) or more of the voting capital stock, or like equity security. 

  

	1.2	 “Confidential Information” means any information or materials (biological, chemical, or otherwise) of the Parties not generally known to
the public, including any information comprised by those materials and including without limitation, Licensed Technology. 

  

	1.3	 “Field of Use” means the fields of use described in section Al of attached Exhibit A. 

  

	1.4	 “Licensed Patent” means the patents and patent applications listed in section A2 of attached Exhibit A along with any further
related patent issued during the term of this Agreement by the United States Patent and Trademark Office or any like foreign body with respect to patent applications. The term “Licensed Patent” also includes any divisionals, continuations,
reissues, renewals, substitutions, re-examinations or extensions and foreign equivalents thereof or substitute therefore of a Licensed Patent. 

  

	1.5	 “Licensed Product” means any product, good or service in the Field of Use that is used, made by, made for, sold, transferred, offered for
sale, or otherwise disposed of by the Company during the term of this Agreement that, but for the granting of the rights set forth in this Agreement, would infringe (including under the doctrine of equivalents) one or more Valid Claims of a Licensed
Patent in the country where such product, good or service is sold or provided, or any product or good that is made using a process or

  

					
		  	1	  	 UW/Osmetech Non-Exclusive Patent License Agreement
 UW Reference 7063-18921A
 Original Two of Two
 Page 1 of 16

	 	 
machine that is covered by a Valid Claim of a Licensed Patent in the country where such product or good is sold or manufactured. 

  

	1.6	 “Licensed Technology” means collectively the inventions claimed in each Licensed Patent. 

  

	1.7	 “Net Sales Price” means the gross amount invoiced for sales, leases, services, and other dispositions of Licensed Products less
(i) all trade, quantity, and cash discounts actually allowed, including (ii) all credits and allowances actually granted due to rejections, returns, billing errors, and retroactive price reductions, (iii) duties, and (iv) excise,
sale and use taxes, and equivalent taxes. In the event the Company sells, leases, or disposes of a Licensed Product to an Affiliate, the “Net Sales Price” for that transaction for purposes of this Agreement shall be equal to the price the
Company charges non-Affiliate Third Parties for the Licensed Product or if the Company does not offer to sell the Licensed Product to the public, the price charged by the Company for a product of similar kind, quality, and quantity.

  

	1.8	 “Payment” means a payment to be made by the Company to the University specified in section 6.1 of this Agreement and described in
section A3 of attached Exhibit A. 

  

	1.9	 “Territory” means worldwide. 

  

	1.10	 “Third Party” means any individual or entity other than the University or the Company. 

  

	1.11	 “Valid Claim” means (a) a claim in an issued and unexpired patent included in the Licensed Patents that: (i) has not been held
unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction, and not subject to appeal, (ii) has not been admitted to be invalid or unenforceable through reissue or disclaimer or
otherwise, (iii) has not been lost through an interference, reexamination or reissue proceeding; or (b) a claim of a pending patent application included in the Licensed Patents. 

 2. Term. The term of this Agreement shall commence on the Effective Date and, unless terminated earlier as provided below in
Article 8, this Agreement shall expire on the date on which no Valid Claim in a Licensed Patent is pending or subsisting in any country in the Territory. 
 3. Grant of License. 
  

	3.1	 The Company’s Rights. 

 3.1.1. Grant. Subject to the terms and conditions of this Agreement, the University hereby grants to the Company, and the Company hereby accepts, a nonexclusive license to
make, have made on its behalf, use, offer to sell or sell, offer to lease or lease, import, or otherwise offer to dispose or dispose of Licensed Products in the Territory. The Parties acknowledge and agree that the license granted in this Agreement

  

					
		  	2	  	 UW/Osmetech Non-Exclusive Patent License Agreement
 UW Reference 7063-18921A
 Original Two of Two
 Page 2 of 16

 
shall be limited to the inventions in the Field of Use that are expressly claimed in each Licensed Patent. No provision of this Agreement shall be construed to grant the Company, by implication,
estoppel or otherwise, any rights other than the rights expressly granted it in this Agreement to the Licensed Technology, a Licensed Patent, or to any other University-owned technology, patent applications, or patents. 
 3.1.2. Sublicensing. Notwithstanding any term of this Agreement to the contrary, the Company shall
not, and shall not have the right to, sublicense its rights under this Agreement. 
  

	3.2	 The United States Government’s Rights. The Parties acknowledge and agree that the federal government of the United States of America has
certain rights in and to any government-funded Licensed Technology as those rights are described in Chapter 18, Title 35 of the United States Code and accompanying regulations, including Part 401, Chapter 37 of the Code of Federal
Regulations, and that the Parties’ rights and obligations under this Agreement to any government-funded Licensed Technology, including the grant of license set forth above in subsection 3.1.1, are subject to the applicable terms of the
aforementioned United States laws. 

  

	3.3	 The University’s Rights. The University retains an irrevocable, nonexclusive license to make, have made, and use products, processes,
and other subject matter covered by the Licensed Patents or the Licensed Technology for research, medical, instructional, or any other academic purpose, including publications. 

 4. Applications and Patents. 
  

	4.1	 Cost Reimbursement. The Company shall pay, or shall reimburse the University for paying, reasonable and necessary costs (including
attorneys’ and application fees) incurred prior to, on, or after the Effective Date to apply for, prosecute, enforce, and maintain each Licensed Patent in those countries where the Company intends to commercialize Licensed Product, as provided
for in section A3.6 of attached Exhibit A. For the avoidance of doubt, the Company shall pay, or shall reimburse the University for paying, costs related to Licensed Patents unless and until the Company notifies the University in writing
of its decision to opt-out of patent protection for a specific country in the Territory. In this event, the Company shall not be responsible for reimbursing those costs and lose rights in that country. 

  

	4.2	 Pre-Agreement Licensed Product Sales. The Company agrees to pay royalties in the amounts set forth in this Agreement for any Licensed
Products it has sold in the Territory prior to the Effective Date. 

  

	4.3	 Patent Application Filings during the Term of this Agreement. 

 4.3.1. The University retains the sole and exclusive right to file or otherwise prosecute patent applications
with respect to the Licensed Technology. In no event shall

  

					
		  	3	  	 UW/Osmetech Non-Exclusive Patent License Agreement
 UW Reference 7063-18921A
 Original Two of Two
 Page 3 of 16

 
the Company file a patent application with respect to the Licensed Technology if a University employee is an inventor on the patent application. 
 4.3.2. The University shall determine in which countries the University will file, or cause to be filed, a
patent application with respect to the Licensed Technology. The Company may request patent prosecution to be pursued in any given country. The Company will specify in writing which of these countries it wishes to receive license from and shall pay
pro-rata share of patent costs as specified in section A3.6 of attached Exhibit A. For the avoidance of doubt, Company shall pay, or shall reimburse the University for paying costs related to Licensed Patents in all countries until the
Company notifies the University in writing of its decision to opt-out of said cost reimbursement for any specific country. 
 4.3.3. For each patent application with respect to the Licensed Technology filed in a particular country, the University shall retain counsel of its choice to file and prosecute such patent application;
the University shall take all commercially reasonable steps to cause a patent application to be filed and a patent to be issued in that country. The Company promptly shall reimburse the University for the University’s out-of-pocket costs,
including application and attorneys’ fees, to file, prosecute and maintain such patent application and issued patent during the term of this Agreement as provided for in section A3.4 of attached Exhibit A. 
 4.3.4. No provision of this Agreement limits, conditions, or otherwise affects the University’s right to
prosecute a patent application with respect to the Licensed Technology in any country. 
  

	4.4	 Maintenance of Licensed Patents. The University shall take all commercially reasonable steps to cause each Licensed Patent to remain or be
valid and subsisting. 

  

	4.5	 Ownership of the Licensed Patents. No provision of this Agreement grants the Company any rights, titles, or interests (except for the grant
of license in subsection 3.1.1 of this Agreement) in the Licensed Patents, notwithstanding the Company’s payment of all or any portion of the patent prosecution, maintenance, and related costs. 

 5. Commercialization. 
  

	5.1	 Commercialization Efforts. The Company shall use its commercially reasonable efforts, consistent with sound and reasonable business practices
and judgment, to commercialize the Licensed Technology and to manufacture and offer to make and sell Licensed Products as soon as practicable and to maximize sales thereof. 

  

	5.2	 Covenants Regarding the Manufacture of Licensed Products. The Company hereby covenants and agrees that the manufacture, use, sale, or
transfer of Licensed Products shall comply with all applicable federal and state laws, including all federal export laws and regulations. The Company hereby further covenants and agrees that, to the extent required by 35 United States Code
Section 204, it shall substantially manufacture in the

  

					
		  	4	  	 UW/Osmetech Non-Exclusive Patent License Agreement
 UW Reference 7063-18921A
 Original Two of Two
 Page 4 of 16

	 	 
United States of America all products embodying or produced through the use of an invention that is subject to the rights of the federal government of the United States of America.

  

	5.3	 Commercialization Reports. Throughout the term of this Agreement, the Company shall deliver to the University written reports of the
Company’s efforts and plans to commercialize the Licensed Technology and to manufacture, offer to sell, or sell Licensed Products, including a projected timeline of development and sales. Prior to product introduction, these reports will be
delivered to the University every six (6) months from the first anniversary of the Effective Date, and then annually, within thirty (30) days of the anniversary of the Effective Date, after first product sale. 

 

	5.4	 Use of the University’s Name and Trademarks or the Names of University Faculty, Staff, or Students. No provision of this Agreement
grants the Company any right or license to use the name or trademarks of the University or the names, or identities of any member of the faculty, staff, or student body of the University. The Company shall not use any such trademarks, names, or
identities without the University’s and, as the case may be, such member’s prior written approval. 

 6. Payments, Reimbursements, Reports, and Records. 
  

	6.1	 Payments. The Company shall deliver to the University the payment or payments specified in section A3 of attached Exhibit A. The
Company shall make such payments by check, wire transfer, or any other mutually agreed-upon and generally accepted method of payment. All checks to the University shall be made payable to “University of Washington” and shall be mailed to
the address specified in Article 21 of this Agreement and shall include the University agreement number l8921A. Upon request, the University shall deliver to the Company written wire transfer instructions. 

  

	6.2	 Late Payments. Company agrees to pay a late fee for all amounts owed to the University that are overdue by thirty (30) days or more. The
late fee shall be computed as the United States prime rate plus Two Percent (2%), compounded monthly, as set forth by The Wall Street Journal (Western edition) on the date on which such payment is due, of the outstanding, unpaid balance. The
payment of such a late fee shall not foreclose or limit University from exercising any other rights it may have as a consequence of the lateness of any payment. 

  

	6.3	 Sales Reports. Within thirty (30) days after the last day of a calendar quarter during the term of this Agreement, the Company shall
deliver to the University a written sales report (a copy of the form of which is attached as Exhibit B) recounting the number and Net Sales Price amount (expressed in U.S. dollars) of all sales, leases, or other dispositions of Licensed
Products made by the Company during such calendar quarter. The Company shall deliver such written report to the University even if the Company is not required hereunder to pay to the University a payment for sales, leases, or other dispositions of
Licensed Products during the calendar quarter. 

  

					
		  	5	  	 UW/Osmetech Non-Exclusive Patent License Agreement
 UW Reference 7063-18921A
 Original Two of Two
 Page 5 of 16

	6.4	 Records Retention and Audit Rights. 

 6.4.1. Throughout the term of this Agreement and for five (5) years thereafter, the Company, at its expense, shall keep and maintain complete and accurate records of all sales,
leases, and other dispositions of Licensed Products during the term of this Agreement and all other records related to this Agreement. 
 6.4.2. The University, at its expense except as set forth below in this subsection, shall have the right to inspect and audit the Company’s records referred to in subsection 6.4.1 hereof at the
Company’s address as set forth in Article 21 of this Agreement or such other locations as the Parties shall mutually agree during the Company’s normal business hours. The University shall have the right to determine the Company’s
compliance with the terms of this Agreement. The Company shall reimburse the University for all its out-of-pocket expenses to inspect and audit such records if the University, in accordance with the results of such inspection and audit, determines
that the Company has underpaid amounts owed to the University by at least *** , in a reporting period. In connection with, and prior to the commencement of, an audit, if the Company so requests in writing to the University, the Company, the
University and the auditor shall enter into an agreement prohibiting the auditor and the University from disclosing the Company’s nonpublic, proprietary information to any Third Party without the Company’s prior written consent; provided,
however, that consistent with generally accepted auditing standards and the auditor’s professional judgment, the auditor may disclose such information to the University and its agents, counsel, or consultants. The Company acknowledges that such
an agreement is adequate to protect its legitimate interests, and the Parties agree that there shall be no additional nondisclosure agreement demanded as a condition to the commencement of an audit and the University’s exercising its rights
under this subsection. 
  

	6.5	 Currency and Checks. All computations and payments made under this Agreement shall be in United States dollars. The exchange rate for the
currency into dollars as reported in the Wall Street Journal as the New York foreign exchange mid-range rate on the last business day of the month in which the transaction was entered into shall be used for determining the dollar value of
transactions conducted in non-United States dollar currencies. 

 7. Third Party Infringement of Licensed
Patent. 
  

	7.1	 Notice of Third Party’s Infringement. In the event the Company learns of substantial, credible evidence that a Third Party is making,
using, or selling a product in a Field of Use in the Territory that infringes a Licensed Patent, the Company promptly thereafter shall deliver written notice of the possible infringement to the University, describing the information suggesting
infringement of the Licensed Patent. 

  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

  

					
		  	6	  	 UW/Osmetech Non-Exclusive Patent License Agreement
 UW Reference 7063-18921A
 Original Two of Two
 Page 6 of 16

	7.2	 Legal Action to Enforce a Licensed Patent. The University shall have no obligation under this Agreement to commence or maintain a suit
against any alleged infringer of Licensed Patents. The University reserves the right to grant a license to the infringer to settle a University-initiated action. No provision of this Agreement shall limit, condition, or otherwise affect the
University’s statutory and common-law rights to commence an action to enforce a Licensed Patent. 

 8.
Termination. 
  

	8.1	 By the University. 

 8.1.1. If the Company breaches or fails to perform one or more of its duties under this Agreement, the University may deliver to the Company a written notice of default. The
University may terminate this Agreement by delivering to the Company a written notice of termination if the default has not cured in full within sixty (60) days of the delivery to the Company of the notice of default. 
 8.1.2. The University may terminate this Agreement by delivering to the Company a written notice of
termination at least ten (10) days prior to the date of termination if the Company (i) becomes insolvent; (ii) voluntarily files or has filed against it a petition under applicable bankruptcy or insolvency laws that the Company fails
to have released within thirty (30) days after filing; (iii) proposes any dissolution, composition, or financial reorganization with creditors or if a receiver, trustee, custodian, or similar agent is appointed; or (iv) makes a
general assignment for the benefit of creditors. 
  

	8.2	 By the Company. The Company may terminate this Agreement at any time by delivering to the University a written notice of termination at least
sixty (60) days prior to the effective date of termination. 

  

	8.3	 Post-termination Period. The Company shall not use, or permit others to use, the Licensed Technology or manufacture or have manufactured
Licensed Products after the termination of this Agreement under section 8.1 or 8.2. After the termination of this Agreement under section 8.1 or 8.2, the Company shall not offer to sell and sell, offer to lease and lease, and otherwise
offer to dispose of or dispose of Licensed Products in the Territory that were manufactured prior to the of this Agreement. 

 9. Release, Indemnification, and Insurance. 
  

	9.1	 The Company’s Release. For itself and its employees, the Company hereby releases the University and its regents, employees, and agents
forever from any and all suits, actions, claims, liabilities, demands, damages, losses, or expenses (including reasonable attorneys’ and investigative expenses) relating to or arising out of (i) the manufacture, use, lease, sale, or other
disposition of a Licensed Product; (ii) the assigning or licensing of the Company’s rights under this Agreement; or (iii) with the exception of the

  

					
		  	7	  	 UW/Osmetech Non-Exclusive Patent License Agreement
 UW Reference 7063-18921A
 Original Two of Two
 Page 7 of 16

	 	 
warranties set forth in section 10.1 of this Agreement, the University’s performance of its obligations hereunder. 

  

	9.2	 Indemnification. Throughout the term of this Agreement and thereafter, the Company shall indemnify, defend, and hold the University and its
regents, employees, and agents harmless from all suits, actions, claims, liabilities, demands, damages, losses, or expenses (including reasonable attorneys’ and investigative expenses), relating to or arising out of any default in the
performance of any material term or provision herein. In addition, throughout the term of this Agreement and thereafter, the Company shall indemnify, defend, and hold the University and its regents, employees, and agents harmless from all suits,
actions, claims, liabilities, demands, damages, losses, or expenses (including reasonable attorneys’ and investigative expenses), relating to or arising out of the manufacture, use, lease, sale, or other disposition of a Licensed Product,
including, without limitation, breach of contract and warranty and products-liability claims relating to a Licensed Product. 

  

	9.3	 The Company’s Insurance. Throughout the term of this Agreement, or during such period as the Parties shall agree in writing, the Company
shall maintain in full force and effect comprehensive general liability (CGL) insurance, consistent with sound business practices. Such insurance policy shall include coverage for claims that may be asserted by the University against the Company
under section 9.2 of this Agreement and for claims by a Third Party against the Company or the University arising out of the purchase or use of a Licensed Product. Such insurance policy shall name the University as an additional insured. Such
insurance policy shall require the insurer to deliver written notice to the University at the address set forth in Article 21 of this Agreement, at least forty-five (45) days prior to the termination of the policy. The Company shall
deliver to the University a copy of the certificate of insurance for such policy. 

 10. Warranties. 

  

	10.1	 Authority. Each Party represents and warrants to the other Party that it has full corporate power and authority to execute, deliver, and
perform this Agreement, and that no other corporate proceedings by such Party are necessary to authorize the Party’s execution or delivery of this Agreement. 

  

	10.2	 Disclaimers. 

 10.2.1. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN SECTION 10.1 OF THIS AGREEMENT, THE UNIVERSITY DISCLAIMS AND EXCLUDES ALL WARRANTIES, EXPRESS AND IMPLIED, CONCERNING THE LICENSED
TECHNOLOGY, EACH LICENSED PATENT, EACH PATENT APPLICATION, AND EACH LICENSED PRODUCT, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF NON-INFRINGEMENT, NONINTERFERENCE AND THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.

  

					
		  	8	  	 UW/Osmetech Non-Exclusive Patent License Agreement
 UW Reference 7063-18921A
 Original Two of Two
 Page 8 of 16

 10.2.2. The University expressly disclaims any warranties
concerning and makes no representations: 
 10.2.2.1. that the Licensed Patents will be approved or will issue;

 10.2.2.2. concerning the validity or scope of any Licensed Patent; or 
 10.2.2.3. that the manufacture, use, sale, lease or other disposition of a Licensed Product will not infringe a Third
Party’s patent or violate its intellectual property rights. 
 10.2.3. The Company
specifically acknowledges the existence of possibly interfering patent rights of Third Parties, including, without limitation, certain patent rights of University of North Carolina (Patent Application Number WO2005030039A2) and Academica Sinica
(Patent Application Number WO2006069339A2). 
  

	11.	 Damages. 

  

	11.1	 Remedy Limitation. EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, IN NO EVENT SHALL THE UNIVERSITY BE LIABLE FOR (A) PERSONAL
INJURY OR PROPERTY DAMAGES ARISING IN CONNECTION WITH THE ACTIVITIES CONTEMPLATED IN THIS AGREEMENT OR (B) LOST PROFITS, LOST BUSINESS OPPORTUNITY, INVENTORY LOSS, WORK STOPPAGE, LOST DATA OR ANY OTHER RELIANCE OR EXPECTANCY, DIRECT OR
INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES, OF ANY KIND. 

  

	11.2	 Damage Cap. IN NO EVENT SHALL THE UNIVERSITY’S TOTAL LIABILITY FOR THE BREACH OR NONPERFORMANCE OF THIS AGREEMENT EXCEED THE AMOUNT
OF PAYMENTS PAID TO THE UNIVERSITY UNDER SECTION 6.1 OF THIS AGREEMENT. THIS LIMITATION SHALL APPLY TO CONTRACT, TORT, AND ANY OTHER CLAIM OF WHATEVER NATURE. 

 12. Amendment and Waiver. This Agreement may be amended from time to time only by a written instrument signed by the Parties. No term or provision of this Agreement
shall be waived and no breach excused unless such waiver or consent shall be in writing and signed by the Party claimed to have waived or consented. No waiver of a breach shall be deemed to be a waiver of a different or subsequent breach.

 13. Assignment. The Company, without the prior approval of the University, may assign all, but no less than
all, its rights and delegate all, but no less than all, its duties under this Agreement to another if (i) the Company or its successors delivers to the University written notice of the actual assignment at least ninety (90) days prior to
the effective date of the event described below in part (ii) of this paragraph, and (ii) the assignment is made as a part of and in connection with (A) the sale by the Company of all or substantially all of its assets to a single
purchaser, (B) the sale, transfer, or exchange by the shareholders, partners, or equity owners of the Company of

  

					
		  	9	  	 UW/Osmetech Non-Exclusive Patent License Agreement
 UW Reference 7063-18921A
 Original Two of Two
 Page 9 of 16

 
a majority interest in the Company to a single purchaser, or (C) the merger of the Company into another corporation or other business entity. Any assignment made in violation of this
subsection shall be void and shall, without further act, cause the immediate termination of this Agreement. 
 This
Agreement shall inure to the benefit of the Company and the University and trustees. 
 14. Applicable Law. The
internal laws of the state of Washington shall govern the validity, construction, and enforceability of this Agreement, without giving effect to the conflict of laws principles thereof. 
 15. Confidentiality. 
  

	15.1	 Form of transfer. Confidential Information may be conveyed in written, graphic, oral, physical, or electronic form. Confidential Information
shall include, without limitation, Licensed Technology as well as Company’s business plan or reports. Company and University must clearly mark its Confidential Information “confidential.” If a disclosing Party communicates
Confidential Information orally, the disclosing Party shall reduce such oral communications to writing of disclosure to the receiving Party and clearly mark it “confidential” and provide a copy to the receiving Party within thirty
(30) days at the address in Article 21. 

  

	15.2	 Exceptions. Confidential Information does not include: any information that: is required by law to be disclosed; is or becomes part of the
public domain through no fault of recipient; is known to recipient prior to the disclosure by the disclosing Party, as evidenced by documentation; is publicly released as authorized under this Agreement by the University, its employees or agents; is
subsequently obtained by a Party from a Third Party who is authorized to have such information; or is independently developed by a Party without reliance on any portion of the Confidential Information received from the disclosing Party and without
any breach of this Agreement as evidenced by documentation. 

  

	15.3	 No Unauthorized Disclosure of Confidential Information. Beginning on the Effective Date and continuing throughout the term of this Agreement
and thereafter for a period of five (5) years (“Confidentiality Period”), neither Party shall disclose or otherwise make known or available to any Third Party or Affiliate any Confidential Information, without the express prior
written consent of the other. In no event shall either Party incorporate or otherwise use Confidential Information in connection with any patent application filed by or on behalf of the other. Both Parties shall utilize reasonable procedures to
safeguard the Confidential Information. 

  

	15.4	 Access to University Information. The University is an agency of the State of Washington and is subject to the Washington Public Records Act,
RCW 42.56 et seq., (“Act”), and no obligation assumed by the University under this Agreement shall be deemed to be inconsistent with the University’s obligations as defined under the Act and as interpreted by the University in its
sole discretion. In the event the University receives

  

					
		  	10	  	 UW/Osmetech Non-Exclusive Patent License Agreement
 UW Reference 7063-18921A
 Original Two of Two
 Page 10 of 16

	 	 
a request for public records under the Act for documents containing Confidential Information, and if the University concludes that the documents are not otherwise exempt from public disclosure,
the University will provide the Company notice of the request before releasing such documents. Such notice shall be provided in a timely manner to afford the Company sufficient time to review such documents and/or seek a protective order, at the
Company’s expense utilizing the procedures described in RCW 42.56.540. The University shall have no obligation to protect the Confidential Information from disclosure in response to a request for public records. 

 16. Consent and Approvals. Except as otherwise expressly provided, all consents or approvals required under the terms of this
Agreement shall be in writing and shall not be unreasonably withheld or delayed. 
 17. Construction. The headings
preceding and labeling the sections of this Agreement are for the purpose of identification only and shall not in any event be employed or used for the purpose of construction or interpretation of any portion of this Agreement. As used herein and
where necessary, the singular shall include the plural and vice versa, and masculine, feminine, and neuter expressions shall be interchangeable. 
 18. Enforceability. If a court of competent jurisdiction adjudges a provision of this Agreement unenforceable, invalid, or void, such determination shall not impair the enforceability of any
of the remaining provisions hereof and such provisions shall remain in full force and effect. 
 19. Entire Agreement;
No Third-Party Beneficiaries. This Agreement (including all attachments, exhibits, and amendments hereto) is intended by the Parties as the final and binding expression of their contract and agreement and as the complete and exclusive statement
of the terms thereof. This Agreement cancels, supersedes, and revokes all prior negotiations, representations and agreements among the Parties, whether oral or written, relating to the subject matter of this Agreement. 
 Company has evaluated the Licensed Technology under a Confidentiality Agreement (“Confidentiality Agreement”) with University
(UWIL # 18127A) with an effective date of August 2, 2006. Confidentiality Agreement is hereby supplanted entirely by this Agreement. 
 No provision of this Agreement, express or implied, is intended to confer upon any person other than the Parties to this Agreement any rights, remedies, obligations, or liabilities hereunder. 

20. Language and Currency. Unless otherwise expressly provided in this Agreement, all notices, reports, and other documents
and instruments that a Party hereto elects or is required by the terms of this Agreement to deliver to the other Party hereto shall be in English, and all notices, reports, and other documents and instruments detailing revenues and earned under this
Agreement or expenses chargeable to a Party hereto shall be United States dollar denominated. 
 21. Notices. All
notices, requests, and other communications that a Party is required or elects to deliver shall be in writing and shall be delivered personally, or by facsimile or

  

					
		  	11	  	 UW/Osmetech Non-Exclusive Patent License Agreement
 UW Reference 7063-18921A
 Original Two of Two
 Page 11 of 16

 
electronic mail (provided such delivery is confirmed), or by a recognized overnight courier service or by United States mail, first-class, certified or registered, postage prepaid, return receipt
requested, to the other Party at its address set forth below or to such other address as such Party may designate by notice given pursuant to this article: 
  

			
	 If to the University:
	  	 UW TechTransfer Invention Licensing
 ATTN: Director
 4311 11th Avenue NE, Suite 500
 Seattle, WA 98105-4608
 Facsimile No.: 206-685-4767

		
	For notices sent pursuant to Article 8, with a copy to:	  	 University of Washington
 Office of the Attorney General
 101 Gerberding Hall
 Seattle, WA 98105
 Facsimile No: 206-543-0779

		
	 If to the Company:
	  	 Osmetech
 ATTN: Legal Department
 757 S. Raymond Ave.
 Pasadena, CA 91105
 Facsimile: 626 463 2012

 22. Publicity. Nothing contained in this Agreement shall be
construed as conferring any right to use in advertising, publicity or other promotional activities any name, trade name, trademark, or other designation of the University without the express written permission of the University, unless such listing
is required under local laws or regulations, provided that the Company may state the existence of this Agreement and the fact that both Parties entered into it. For any use other than the foregoing, the Company hereby expressly agrees not to use the
name “University of Washington” or any contraction, abbreviation, or simulation thereof without prior written approval from an authorized representative of the University. The University shall have the right to report in its customary
publications and presentations that the University and the Company have entered into a license agreement for the Licensed Technology and the University may use the Company logos in such publications and presentations provided that the University
does not modify the Company’s logos and does not through such use imply any endorsement by the Company of the University. 
 23. Relationship of Parties. In entering into, and performing their duties under, this Agreement, the Parties are acting as independent contractors and independent employers. No provision of this Agreement shall create or be
construed as creating a partnership, joint venture, or agency relationship between the Parties. No Party shall have the authority to act for or bind the other Party in any respect. 
 24. Security Interest. In no event shall the Company grant, or permit any person to assert or perfect, a security interest in the Company’s rights under this
Agreement. 
  

					
		  	12	  	 UW/Osmetech Non-Exclusive Patent License Agreement
 UW Reference 7063-18921A
 Original Two of Two
 Page 12 of 16

 25. Survival. Immediately upon the termination or expiration of this
Agreement, all the Company’s rights under this Agreement shall terminate; provided, however, the Company’s obligations that have accrued prior to the effective date of termination or expiration of this Agreement (e.g., the
obligation to report and make payments on sales, leases, or dispositions of Licensed Products and to reimburse the University for costs) and the obligations specified in sections 6.1, 6.2, and A3.1 of the Agreement shall survive. The
obligations and rights set forth in sections 6.4 and 8.3 and articles 9, 10, and 11 of this Agreement shall survive the termination or expiration of this Agreement. 
 26. Collection Costs and Attorneys’ Fees. If a Party shall fail to perform an obligation or otherwise breaches one or more of the terms of this Agreement, the other Party may recover
from the non-performing breaching Party all its costs (including actual attorneys’ and investigative fees) to enforce the terms of this Agreement. 
 27. Forum Selection. A suit, claim, or other action to enforce the terms of this Agreement shall be brought exclusively in the state courts of King County, Washington. The Company hereby
submits to the jurisdiction of that court and waives any objections it may have to that court asserting jurisdiction over the Company or its assets and property. 
 28. Patent Marking. Company shall mark any and all material forms of Licensed Product or packaging pertaining thereto made and sold by Company in the Territory with patent marking confirming
to 35 U.S.C. §287(a), as amended from time to time. Such marking shall further identify the pendency of any U.S. patent application and/or any issued U.S. or foreign patent forming any part of the University rights. All Licensed Product shipped
to or sold in other countries shall be marked in such a manner as to provide notice to potential infringers pursuant to the patent law and practice of the country of manufacture or sale. 
 IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed by their respective authorized representatives. 
  

									
	 University of Washington
	 		 	 Osmetech Molecular Diagnostics

					
	 By:
	 	 /s/ Fiona Wills
	 		 	 By:
	 	 /s/ Edward O. Kreusser

	 Name:
	 	 Fiona Wills
	 		 	 Name:
	 	 Edward O. Kreusser, Esq.

	 Title:
	 	 Interim Director
	 		 	 Title:
	 	 VP, IP and Legal Affairs

					
	 Date:
	 	 February 22, 2007
	 		 	 Date:
	 	 2/28/2007

  

					
		  	13	  	 UW/Osmetech Non-Exclusive Patent License Agreement
 UW Reference 7063-18921A
 Original Two of Two
 Page 13 of 16

 Exhibit A 
 Non-Exclusive Patent License Schedule 
  

	A1.	 Fields of Use (sections 1.2 and 3.1.1): 

 Fields of Use: Human clinical diagnostics field, including Research Use Only (RUO), Investigational Use Only, (IUO), Analyte Specific Reagents (ASR), and In Vitro Diagnostic (IVD)
fields of use for anticoagulant dosing. IVD field of use expressly excludes market for tests performed in the home. Any reagents or kits sold under this Agreement are not for remanufacture, re-kitting, or resale to any Third Party, in whole or part.

  

	A2.	 Licensed Patents (section 1.4): 

  

									
	 Patent Application No.:
	  	 UW Reference #
	  	 Inventors
	  	 Assignee
	  	Application
Date
	 US 10/967,879
	  	 7063P.1US
	  	 Mark Rieder Allan Rettie
	  	 University of Washington
	  	10/18/2004
	 PCT/US2005/037058
	  	 7063P.IPCT
	  	 Mark Rieder Allan Rettie
	  	 University of Washington
	  	10/17/2005
	 US 11/141,288
	  	 7063P.1USCIP1
	  	 Mark Rieder Allan Rettie
	  	 University of Washington
	  	05/31/2005

  

	A3.	 Payments (section 6.1): 

  

	A3.1	 Up-front Payment. The Company shall pay to the University    ***    as an up-front payment. This
up-front payment shall be due as of the Effective Date and payable in    ***    . The first installment shall be payable within thirty (30) days of the Effective Date. The next installment shall be
payable within thirty (30) days of the first anniversary of the Effective Date and the last installment shall be payable within thirty (30) days of the second anniversary of the Effective Date. This up-front payment shall be non-refundable
and not creditable against future royalty obligations and shall survive termination or expiration of this Agreement. 

  

	A3.2	 Running Royalty Payments. The Company shall pay to the University within thirty (30) days after the last day of each calendar quarter
during the term of this Agreement an amount equal to    ***    of the Net Sales Price of all sales, leases, or dispositions of Licensed Products made by the Company during such quarter as a running royalty
payment. In the event that Company is required to pay royalties to one or more Third Parties as necessary to avoid infringement thereof by the manufacture, use, or sale of any Licensed Products, or to avoid infringement-related litigation with
respect to such patents, then the running royalty rate specified shall be reduced by an amount equal to one-half of the royalties actually paid to the Third Party, provided that in no event shall the royalties otherwise due to the University be less
than    ***    of the royalties that 

  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

  

					
		  	14	  	 UW/Osmetech Non-Exclusive Patent License Agreement
 UW Reference 7063-18921A
 Original Two of Two
 Page 14 of 16

	 	 
would be payable to the University were the University the sole licensor with respect to such Licensed Products. For the avoidance of doubt, under no circumstance shall the royalty to the
University be less than    ***    of Net Sales Price following such reduction. 

  

	A3.3	 Combination Products. If a Licensed Product is sold in combination with one or more other products or components that is not a Licensed
Product, Net Sales Price shall be calculated by multiplying Net Sales Price for such combination product by the fraction    ***    where A is the invoice price if the Licensed Product is sold separately, and B
is the aggregate invoice price of any other active component or components, or devices, in the combination if sold separately, or if either of the products are not sold separately, than the allocation shall be commercially reasonable and determined
by good faith negotiation between the University and the Company. Notwithstanding the foregoing, in no event shall the royalties due the University be less than *** of what would otherwise be due if the Licensed Product was sold as an individual
product. 

  

	A3.4	 Annual Minimum Royalty Payments. The Company shall pay to the University within thirty (30) days after each anniversary of the Effective
Date, annual minimum royalties, to be creditable against running royalties for the preceding year on a non-cumulative basis, as set forth in the following table: 

  

			
	 Due on Anniversary Date of Year #:
	  	$ Amount in USD
	 1
	  	***
	 2
	  	***
	 3
	  	***
	 4
	  	***
	 5 and each year thereafter
	  	***

  

	A3.6	 Patent Prosecution Reimbursements: The Company shall pay to the University within thirty (30) days after the Effective Date,
    ***    in full satisfaction of costs (including attorneys’ and application fees) incurred prior to the Effective Date to apply for, prosecute, enforce, and maintain each Licensed Patent in those
countries where Company intends to commercialize Licensed Product pursuant to section 4.1 of this Agreement. This payment shall be non-refundable and not creditable against the Company’s other patent prosecution payment obligations. The
Company shall be responsible for its pro-rata share of ongoing patent costs, determined by the number of other licensees at the time such fees and costs were incurred, for such patent or patent application. Pro-rata share shall be calculated for
each country the Company requests a license. 

  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

  

					
		  	15	  	 UW/Osmetech Non-Exclusive Patent License Agreement
 UW Reference 7063-18921A
 Original Two of Two
 Page 15 of 16

 Exhibit B 
 Royalty Report Form 
 Date 
 Company Name & Address 
  

					
	License Number	  	  
	  	

  

			
	 Reporting Period:
	  	 Report Due Date:

 This report must be submitted regardless of whether royalties are owed. Please do not leave any column blank. State all information requested below. 
  

							
	 Product Description
	  	Royalty Rate	  	Quantity/
Net Sales	  	Royalty Due
		  		  		  	

  

											
	 Report Completed by:
	  	 	  		 	 Total Royalties Due:
	 	 	  	
						
	 Telephone Number:
	  	 	  		 		 		  	

 If you have questions please contact: 
 Please make check payable to: University of Washington 
  

					
		  	16	  	 UW/Osmetech Non-Exclusive Patent License Agreement
 UW Reference 7063-18921A
 Original Two of Two
 Page 16 of 16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]